12/19
08:07 am
imrx
Immuneering Launches Pancreatic Cancer Advisory Board [Yahoo! Finance]
High
Report
Immuneering Launches Pancreatic Cancer Advisory Board [Yahoo! Finance]
12/19
08:00 am
imrx
Immuneering Launches Pancreatic Cancer Advisory Board
High
Report
Immuneering Launches Pancreatic Cancer Advisory Board
12/17
08:05 am
imrx
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025 [Yahoo! Finance]
Low
Report
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025 [Yahoo! Finance]
12/17
08:00 am
imrx
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
Low
Report
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
12/13
02:44 pm
imrx
Morgan Stanley upgrades PTC, cuts Immuneering, Amicus [Seeking Alpha]
Low
Report
Morgan Stanley upgrades PTC, cuts Immuneering, Amicus [Seeking Alpha]
12/13
08:13 am
imrx
Immuneering Co. (NASDAQ: IMRX) was downgraded by analysts at Morgan Stanley from an "equal weight" rating to an "underweight" rating.
High
Report
Immuneering Co. (NASDAQ: IMRX) was downgraded by analysts at Morgan Stanley from an "equal weight" rating to an "underweight" rating.
12/12
08:17 am
imrx
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma [Yahoo! Finance]
High
Report
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma [Yahoo! Finance]
12/12
08:00 am
imrx
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
Medium
Report
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
11/27
08:00 am
imrx
Immuneering to Present at the Piper Sandler 36?? Annual Healthcare Conference
Medium
Report
Immuneering to Present at the Piper Sandler 36?? Annual Healthcare Conference
11/21
03:17 pm
imrx
Immuneering Leads The Pack Of 3 US Penny Stocks To Monitor [Yahoo! Finance]
Low
Report
Immuneering Leads The Pack Of 3 US Penny Stocks To Monitor [Yahoo! Finance]
11/20
06:20 pm
imrx
Immuneering Co. (NASDAQ: IMRX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $13.00 price target on the stock.
Medium
Report
Immuneering Co. (NASDAQ: IMRX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $13.00 price target on the stock.
11/14
08:15 am
imrx
Immuneering Co. (NASDAQ: IMRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $15.00 price target on the stock.
Low
Report
Immuneering Co. (NASDAQ: IMRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $15.00 price target on the stock.
11/13
04:05 pm
imrx
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
High
Report
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
10/15
09:05 am
imrx
Immuneering rises on orphan drug designation for treatment of pancreatic cancer [Seeking Alpha]
Medium
Report
Immuneering rises on orphan drug designation for treatment of pancreatic cancer [Seeking Alpha]
10/15
08:00 am
imrx
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
High
Report
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
10/14
09:44 am
imrx
Here's Why We're A Bit Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Situation [Yahoo! Finance]
Medium
Report
Here's Why We're A Bit Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Situation [Yahoo! Finance]